Search research articles
Contact Us
Filters
Showing results (261-270 of 300) with videos related to
Page
of 30
Sort By:
Diagnostics (Basel, Switzerland)
|
March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC
Andreas Herz, Aymane Khouya, Maja Guberina, et al.
Iscience
|
December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)
Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Oliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
The Lancet Regional Health. Europe
|
November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Anika Kästner, Anna Kron, Neeltje van den Berg, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
International Journal of Cancer
|
August 29, 2024
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)
Christina Schulte, Thomas Gauler, Christoph Pöttgen, et al.
The New England Journal of Medicine
|
June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Giannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Cancer Discovery
|
April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
Robin M J M van Geel, Josep Tabernero, Elena Elez, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 17, 2026
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis
Wilfried Ernst Erich Eberhardt, Christina Schulte, Christoph Pöttgen, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 300) with videos related to
Sort By:
Page
of 30
Diagnostics (Basel, Switzerland)
|
March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC
Andreas Herz, Aymane Khouya, Maja Guberina, et al.
Iscience
|
December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)
Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Oliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
The Lancet Regional Health. Europe
|
November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Anika Kästner, Anna Kron, Neeltje van den Berg, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
International Journal of Cancer
|
August 29, 2024
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)
Christina Schulte, Thomas Gauler, Christoph Pöttgen, et al.
The New England Journal of Medicine
|
June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Giannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Cancer Discovery
|
April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
Robin M J M van Geel, Josep Tabernero, Elena Elez, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 17, 2026
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis
Wilfried Ernst Erich Eberhardt, Christina Schulte, Christoph Pöttgen, et al.
Page
of 30